Amgen’s $AMGN Kyprolis regimen missed primary endpoints in late-stage study in certain multiple myeloma patients. A Phase 3 clinical trial, CLARION, assessing  the combination of Amgen's KYPROLIS  (carfilzomib), melphalan and prednisone (KMP) compared to Takeda's VELCADE (bortezomib), melphalan and prednisone (VMP) over 54 weeks in patients with newly diagnosed multiple myeloma who were ineligible for hematopoietic stem cell transplant failed to accomplish its primary endpoint of a statistically valid increase in progression-free survival (PFS).